Skip to main content

Table 33 Strength of evidence of treatments for anxiety and related disorders in children and adolescents

From: Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

Disorder Antidepressants Benzodiazepines and other treatments
OCD Fluoxetine (Level 1) [12641269] Antipsychotics
  Clomipramine (Level 1) [12741276] Adjunctive aripiprazole (Level 3) 1293
  Citalopram (Level 2) [1264, 1270] Other
  Fluvoxamine (Level 2) 1271 Riluzole (Level 4) 1294
  Paroxetine (Level 2) 1272  
  Sertraline (Level 2) 1273  
Panic disorder   Anxiolytics
   Clonazepam (Level 4) [1287, 1288]
   Alprazolam (Level 4) 1289
SAD Fluoxetine (Level 1) [1227, 1277] Anxiolytics
  Fluvoxamine (Level 2) 1278 Alprazolam (Level 2, -ve) 1290
  Paroxetine (Level 2) 1279  
  Venlafaxine XR (Level 2) 1282  
  Escitalopram (Level 3) 1280  
  Sertraline (Level 3) 1281  
  Mirtazapine (Level 3) 1283  
Separation anxiety disorder Fluoxetine (Level 2) 1277 Anxiolytics
  Fluvoxamine (Level 2) 1278 Clonazepam (Level 2, -ve) 1292
GAD Fluoxetine (Level 2) 1277 Anxiolytics
  Fluvoxamine (Level 2) 1278 Alprazolam (Level 2, -ve) 1290
  Sertraline (Level 2) 1284  
School-refusal Citalopram (Level 4) 1285 Anxiolytics
  Adjunctive imipramine (Level 2) 1259 Alprazolam (Level 2, -ve) 1291
PTSD Sertraline (Level 2, -ve) 1286  
  Adjunctive sertraline (Level 2, -ve) [946]  
  1. XR = extended release; (-ve) = negative.